Drug discovery
- Associate Professor, Teaching and Research Division
Biography 
Dr. Chong obtained his MPhil and PhD in Immunology from the Department of Paediatrics and Adolescent Medicine at The University of Hong Kong. He received his postdoctoral training in immunology from the National Eye Institute at National Institutes of Health (NIH) in Bethesda, MD, USA. After that, he was appointed as the Associate Professor at the Key State Laboratory of Ophthalmology, Sun Yat-sen University in Guangzhou, China. He joined the School of Chinese Medicine, Hong Kong Baptist University, as the Associate Professor in 2022.
+ More InformationResearch Interests
Dr. Chong's research centers on the cellular and molecular mechanism involved in immunoregulation and autoimmunity, and discovering novel therapeutic drug for autoimmune diseases. His works on autoimmunity have been well recognized and published in prestigious journals, including Immunity, Journal of Experimental Medicine, Journal of Autoimmunity, Hepatology and Journal of Infection.
Selected Publications
Zhong YJ, Zhang X, Chong WP** (Corresponding Author). Interleukin-24 Immunobiology and Its Roles in Inflammatory Diseases. Int J Mol Sci. 2022, Int J Mol Sci. 2022 6;23:627. (Impact factor 6.2)
Wu S, Ma R, Zhong Y, Chen Z, Zhou H, Zhou M, Chong WP** (Corresponding Author), Chen J. Deficiency of IL-27 signaling exacerbates experimental autoimmune uveitis with elevated uveitogenic Th1 and Th17 responses. Int J Mol Sci. 2021 14;22:7517. (Impact factor 6.2)
Chen Z, Zhang T, Kam HT, Qiao D, Zhong Y, Jin W, Zhou M, Zhou H, Chong WP, Chen W, Chen J. Induction of antigen-specific Treg cells in treating autoimmune uveitis via bystander suppressive pathways without compromising anti-tumor immunity. EBioMedicine. 2021 16;70:103496. (Impact factor 11.2)
Chong WP, Mattapallil MJ, Raychaudhuri K, Bing SJ, Wu S, Zhong Y, Wang W, Chen Z, Silver PB, Jittayasothorn Y, Chan CC, Chen J, Horai R, Caspi RR. The cytokine IL-17A limits Th17 pathogenicity via a negative feedback loop driven by autocrine induction of IL-24. Immunity. 2020; 53:384-397. (Impact factor 43.4)
Wang W*, Chong WP* (Co-first author), Li C, Chen Z, Wu Z, Zhou H, Wan Y, Chen W, Gery I, Caspi RR, Liu Y, Chen J. Non-redundant requirement for CXCR3 signaling for effective treatment of CNS autoimmunity with type I IFNs. Cell Rep. 2019; 28:486-497. (Impact Factor 10.0)